Stock H02 HAW PAR CORPORATION LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Haw Par Corporation Limited

Equities

H02

SG1D25001158

Pharmaceuticals

Market Closed - Singapore S.E.
Other stock markets
 05:06:33 2024-04-29 am EDT 		5-day change 1st Jan Change
9.86 SGD +0.41% Intraday chart for Haw Par Corporation Limited +1.44% +1.13%
Apr. 23 Haw Par Corporation Limited Announces Board Appointments CI
Feb. 26 Haw Par Corporation Limited Proposes One-Tier Tax-Exempt Second and Final Dividend for the Financial Year Ended 31 December 2023, Payable on 21 May 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,655 2,828 2,367 2,512 2,121 2,158
Enterprise Value (EV) 1 2,158 2,371 1,813 1,916 1,816 1,613
P/E ratio 14.8 x 15.5 x 19.8 x 22.8 x 14.3 x 9.97 x
Yield 2.5% 2.35% 2.8% 2.64% 3.13% 4.1%
Capitalization / Revenue 11.2 x 11.6 x 21.3 x 17.8 x 11.6 x 9.3 x
EV / Revenue 9.07 x 9.72 x 16.3 x 13.6 x 9.97 x 6.95 x
EV / EBITDA 24.1 x 27.8 x 89.5 x 61.5 x 37 x 23.1 x
EV / FCF 45.4 x 36.8 x 122 x 190 x 138 x 50.1 x
FCF Yield 2.2% 2.72% 0.82% 0.53% 0.72% 2%
Price to Book 0.91 x 0.9 x 0.82 x 0.78 x 0.6 x 0.62 x
Nbr of stocks (in thousands) 220,841 221,072 221,187 221,288 221,368 221,368
Reference price 2 12.02 12.79 10.70 11.35 9.580 9.750
Announcement Date 3/27/19 3/31/20 3/31/21 4/5/22 4/3/23 4/1/24
1SGD in Million2SGD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 237.8 244 111 141.2 182.1 232.1
EBITDA 1 89.56 85.21 20.26 31.16 49.06 69.85
EBIT 1 83.26 78.93 13.93 24.7 43.38 64.01
Operating Margin 35.01% 32.35% 12.55% 17.49% 23.82% 27.58%
Earnings before Tax (EBT) 1 192.3 197 124.2 116.2 159 229.4
Net income 1 179.1 182.2 119.8 110.1 148.3 216.6
Net margin 75.3% 74.68% 107.87% 77.99% 81.45% 93.32%
EPS 2 0.8110 0.8240 0.5416 0.4976 0.6700 0.9780
Free Cash Flow 1 47.49 64.39 14.86 10.1 13.14 32.22
FCF margin 19.97% 26.39% 13.39% 7.16% 7.22% 13.88%
FCF Conversion (EBITDA) 53.03% 75.56% 73.34% 32.43% 26.79% 46.13%
FCF Conversion (Net income) 26.52% 35.34% 12.41% 9.18% 8.86% 14.88%
Dividend per Share 2 0.3000 0.3000 0.3000 0.3000 0.3000 0.4000
Announcement Date 3/27/19 3/31/20 3/31/21 4/5/22 4/3/23 4/1/24
1SGD in Million2SGD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 496 457 554 595 305 546
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 47.5 64.4 14.9 10.1 13.1 32.2
ROE (net income / shareholders' equity) 5.96% 5.99% 3.96% 3.61% 4.39% 6.17%
ROA (Net income/ Total Assets) 1.65% 1.57% 0.28% 0.5% 0.78% 1.1%
Assets 1 10,833 11,583 42,594 22,230 18,966 19,606
Book Value Per Share 2 13.30 14.30 13.00 14.50 16.00 15.70
Cash Flow per Share 2 2.350 2.110 2.510 2.690 1.510 2.590
Capex 1 3.36 2.97 7.54 4.38 19.7 7.77
Capex / Sales 1.41% 1.22% 6.79% 3.1% 10.84% 3.35%
Announcement Date 3/27/19 3/31/20 3/31/21 4/5/22 4/3/23 4/1/24
1SGD in Million2SGD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
HAW PAR CORPORATION LIMITED Stock Haw Par Corporation Limited
+1.13% 1.6B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.81% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+13.30% 14.09B
CIPLA LIMITED Stock Cipla Limited
+12.97% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+39.74% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. H02 Stock
  4. Financials Haw Par Corporation Limited